IND 2 Results LLC   Report issue

For profit Phase 2 Phase 3
Founded: Atlanta GA United States (2010)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2015
NCT02578940
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

Fluciclovine (Axumin) (2 trials)

Drugs in Phase 2 Trials (1)

pegloticase (krystexxa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2